Get Help Sign In


IDT launches xGen™ Exome Research Panel v2

Jan 23, 2020
New panel breaks performance and price barriers in exome sequencing

xGen Exome Research Panel v2

CORALVILLE, IA (January 23, 2020)
– Integrated DNA Technologies (IDT), a leading comprehensive genomics solutions provider, has launched its xGen™ Exome Research Panel v2 — delivering the highest and most reliable coverage of the exome at a fraction of the cost. The new panel builds on the consistency of IDT’s extremely popular xGen™ Exome Research Panel v1 with updated content and enhanced performance that meets ISO 13485 standards. Thanks to IDT’s 30 years of synthesis innovation and commitment to quality, the xGen Exome Research Panel v2 was made at an unheard-of scale to increase sequencing coverage, consistency, and reliability – delivering a significant performance boost and cost savings to researchers.

The xGen Exome Research Panel v2 serves wide-ranging applications such as population studies, rare disease research, and oncology, delivering improved on-target rates and uniformity with increased sample coverage. The panel content has been updated using the most accurate and up-to-date exome reference combined with IDT’s proprietary bioinformatics design pipeline, providing the most even and complete coverage of expertly curated content.

An important benefit for researchers is that all of the xGen Exome Research Panel v2 probes were manufactured for one large synthesis lot. A single synthesis event for all of the probes ensures reproducible results and avoids expensive lot-to-lot revalidations.

Trey Martin, President of IDT commented, “We’re really excited to be launching the xGen Exome Research Panel v2, which breaks both performance and price barriers in exome sequencing. IDT is the only company with the experience and capability to synthesize this quantity of material in a single lot, providing researchers with the deepest and most reliable exome coverage without the lot-dependent dropouts common to array-based platforms. The fact that researchers can rely on material from one synthesis lot without having to revalidate is key to saving time, money, and getting the all-important consistency and reproducible results.”

IDT is the only company capable of manufacturing this quantity of material in a single synthesis event – literally tens of millions of samples – supporting research programs for years with the highest reliability and lowest price in the industry. All of the 415,115 probes in the xGen Exome Research Panel v2 are individually synthesized on IDT’s newest platform, Gemini, which is the company’s sixth-generation synthesis platform. The probes go through individual quality control by ESI-MS, quantification, and are pooled, ensuring unprecedented quality and performance. This single synthesis event assures consistent and reproducible exome sequencing for years – saving researchers both time and money on expensive revalidations. In contrast, array-based panels vary in content and performance from lot to lot because they are produced on a small scale, requiring researchers to constantly revalidate products at considerable cost and risk potentially inconsistent results. 

IDT also recognizes that exome solutions are not one size fits all and offers a spectrum of customization options. Researchers often need to add custom content for important locations outside coding regions, such as promoters, intronic SNPs, and more. IDT can help researchers add custom content to the exome using NGS Discovery Pools for pilot studies, plus IDT can build and inventory custom exome panels using Lockdown™ Probe Pools should customers need GMP manufacturing. Even with customization, researchers get the same level of consistency and performance to build with confidence.  
A recent partnership with SOPHiA GENETICS leverages the power of the xGen Exome Research Panel v2. By combining SOPHiA’s sophisticated tools to assist with data analysis and interpretation along with the new panel, labs now have access to a solution for getting the best exome data available on the market. This solution for clinical researchers is key for the entire precision medicine journey, from discovery to diagnostics.  

IDT’s xGen Exome Research Panel v2 is extremely cost-effective with a retail price of $8 per sample, representing a >50% reduction cost over v1 of the Panel, which is the result of efficiencies delivered from the new Gemini synthesis platform. This savings contributes to IDT’s ability to offer one of the most price-friendly complete sequencing workflows on the market.  

IDT is an operating company within Danaher Corporation’s (NYSE: DHR) Life Sciences platform. For more information, please visit

Follow IDT on twitter @idtdna for real-time updates and insights.

About IDT
Integrated DNA Technologies, Inc. (IDT)
develops, manufactures, and markets nucleic acid products for the life sciences industry in the areas of academic and commercial research, agriculture, medical diagnostics, and pharmaceutical development. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Through its GMP services, IDT manufactures products used by researchers in diagnostic tests for many forms of cancer and most inherited and infectious diseases. IDT is widely recognized as the industry leader in custom nucleic acid manufacture, serving over 120,000 life sciences researchers. IDT has its manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Leuven, Belgium; and Singapore.

Brian Werger
Manager of Public Relations
800-328-2661 (US & Canada)
+1 319-626-8400 (outside US)  

About Danaher Corporation
is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, including IDT, Danaher’s globally diverse team of approximately 71,000 associates is united by a common culture and operating system, the Danaher Business System, and our Shared Purpose, Helping Realize Life’s Potential. For more information, please visit 


Learn about IDT's role in the fight against COVID-19

Media and PR

For media inquiries please contact IDT Public Relations,

*RUO—For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend for these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.